From this Monday, June 15, French patients will be able to benefit from reimbursement for Wegovy (Novo Nordisk) and Mounjaro (Eli Lilly), two drugs indicated in the treatment of obesity. Both are GLP-1 analogs, a class of treatments that act in particular on the regulation of appetite and promote significant weight loss.
This article is reserved for subscribers
Would you like to read more? Subscribe without obligation to our digital offer
I subscribe
If you are an authorized partner, subscribed to Le Monde, or if you wish to obtain authorization to access this content, please contact: licensinggroupelemonde.fr by attaching a copy...
If you are an authorized partner, subscriber to Le Monde, or if you wish to obtain authorization to access this content, please contact: licensinggroupelemonde.fr by attaching a copy...
The Nepalese mountaineer who miraculously survived a week alone on the slopes of Everest, including three days at the bottom of a crevasse, told AFP how he managed...
If you are an authorized partner, subscribed to Le Monde, or if you wish to obtain authorization to access this content, please contact: licensinggroupelemonde.fr by attaching a copy...
Get the latest mobile and technology news and updates from around the world on Paudal Stay updated with news on computers, apps, games, gadgets, smartphones, and other personal technology trends.
